ScinoPharm Taiwan (Taiwan) Performance
| 1789 Stock | TWD 23.40 0.05 0.21% |
The entity has a beta of 0.21, which indicates not very significant fluctuations relative to the market. As returns on the market increase, ScinoPharm Taiwan's returns are expected to increase less than the market. However, during the bear market, the loss of holding ScinoPharm Taiwan is expected to be smaller as well. At this point, ScinoPharm Taiwan has a negative expected return of -0.12%. Please make sure to validate ScinoPharm Taiwan's mean deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if ScinoPharm Taiwan performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ScinoPharm Taiwan has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 4.1 B | |
| Total Cashflows From Investing Activities | -70 M | |
| Free Cash Flow | 188.5 M |
ScinoPharm |
ScinoPharm Taiwan Relative Risk vs. Return Landscape
If you would invest 2,535 in ScinoPharm Taiwan on September 1, 2024 and sell it today you would lose (195.00) from holding ScinoPharm Taiwan or give up 7.69% of portfolio value over 90 days. ScinoPharm Taiwan is generating negative expected returns and assumes 0.9864% volatility on return distribution over the 90 days horizon. Simply put, 8% of stocks are less volatile than ScinoPharm, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
ScinoPharm Taiwan Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ScinoPharm Taiwan's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ScinoPharm Taiwan, and traders can use it to determine the average amount a ScinoPharm Taiwan's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1238
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 1789 |
Estimated Market Risk
| 0.99 actual daily | 8 92% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ScinoPharm Taiwan is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ScinoPharm Taiwan by adding ScinoPharm Taiwan to a well-diversified portfolio.
ScinoPharm Taiwan Fundamentals Growth
ScinoPharm Stock prices reflect investors' perceptions of the future prospects and financial health of ScinoPharm Taiwan, and ScinoPharm Taiwan fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ScinoPharm Stock performance.
| Return On Equity | 0.0295 | |||
| Return On Asset | 0.0184 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.12 % | |||
| Current Valuation | 16.28 B | |||
| Shares Outstanding | 790.74 M | |||
| Price To Earning | 51.64 X | |||
| Price To Book | 1.92 X | |||
| Price To Sales | 6.90 X | |||
| Revenue | 2.76 B | |||
| EBITDA | 690.37 M | |||
| Cash And Equivalents | 4.72 B | |||
| Cash Per Share | 5.97 X | |||
| Total Debt | 2.29 B | |||
| Debt To Equity | 21.10 % | |||
| Book Value Per Share | 13.15 X | |||
| Cash Flow From Operations | 509.82 M | |||
| Earnings Per Share | 0.39 X | |||
| Total Asset | 11.69 B | |||
| Retained Earnings | 1.05 B | |||
| Current Asset | 6.2 B | |||
| Current Liabilities | 2.25 B | |||
About ScinoPharm Taiwan Performance
Evaluating ScinoPharm Taiwan's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if ScinoPharm Taiwan has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ScinoPharm Taiwan has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells CGMP active pharmaceutical ingredients to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. ScinoPharm Taiwan, Ltd. was founded in 1997 and is headquartered in Tainan, Taiwan. SCINOPHARM TAIWAN operates under Drug Manufacturers - Specialty Generic classification in Taiwan and is traded on Taiwan Stock Exchange.Things to note about ScinoPharm Taiwan performance evaluation
Checking the ongoing alerts about ScinoPharm Taiwan for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ScinoPharm Taiwan help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ScinoPharm Taiwan generated a negative expected return over the last 90 days | |
| About 59.0% of the company shares are owned by insiders or employees |
- Analyzing ScinoPharm Taiwan's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ScinoPharm Taiwan's stock is overvalued or undervalued compared to its peers.
- Examining ScinoPharm Taiwan's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ScinoPharm Taiwan's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ScinoPharm Taiwan's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ScinoPharm Taiwan's stock. These opinions can provide insight into ScinoPharm Taiwan's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ScinoPharm Stock Analysis
When running ScinoPharm Taiwan's price analysis, check to measure ScinoPharm Taiwan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ScinoPharm Taiwan is operating at the current time. Most of ScinoPharm Taiwan's value examination focuses on studying past and present price action to predict the probability of ScinoPharm Taiwan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ScinoPharm Taiwan's price. Additionally, you may evaluate how the addition of ScinoPharm Taiwan to your portfolios can decrease your overall portfolio volatility.